Brain, Vol. 123, No. 5, 1027-1040,
May 2000
© 2000 Oxford University Press
Kurtzke scales revisited: the application of psychometric methods to clinical intuition
Neurological Outcome Measures Unit, Institute of Neurology, London, UK
Correspondence to:
Dr Jeremy Hobart, Neurological Outcome Measures Unit, Institute of Neurology, Queen Square, London WC1N 3BG, UK E-mail: J.Hobart{at}ion.ucl.ac.uk
When developing his disability scales for multiple sclerosis, Kurtzke demonstrated perception and insight. However, 45 years later, the evaluation of his clinically derived scales remains limited, particularly for more disabled patients. Indeed, many of Kurtzke's assumptions underpinning the development of the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) are untested. This study aims to build on previous work and provide a more detailed examination using psychometric methods of the EDSS and FS. There are three study objectives: (i) to examine comprehensively the psychometric properties of the EDSS in more disabled people with multiple sclerosis undergoing in-patient rehabilitation; (ii) to examine the reliability of the FS and test Kurtzke's assumptions that they measure different aspects of the neurological examination and measure different constructs from that measured by the EDSS; and (iii) to examine whether the FS can be summed to generate a summary score. The EDSS was examined for its acceptability (score distributions), reliability (inter- and intra-rater reproducibility, standard error of measurement), validity (convergent and discriminant validity, measurement precision, discrimination between individuals) and responsiveness (effect size). The FS were examined for their reliability (inter- and intra-rater reproducibility), intercorrelations, correlations with the EDSS and the extent to which they satisfy Likert's criteria as a summed rating scale. In this more disabled sample of people with multiple sclerosis, the EDSS is an acceptable measure but demonstrates limited variability. Inter-rater reproducibility (intraclass correlation coefficient; ICC = 0.78) is adequate for group comparison studies, but intra-rater reproducibility is variable (ICC = 0.62–0.94). Convergent and discriminant validity for the EDSS is supported, but its measurement precision relative to the Functional Independence Measure is limited (56%). Also, the EDSS has a limited ability to distinguish between individuals in terms of their disability and its responsiveness is poor (effect size = 0.10). Results indicate that the FS measure constructs distinct from each other (intercorrelations = –0.23 to +0.52) and from the EDSS (correlations = –0.10 to +0.59). Intra-rater, but not inter-rater reproducibility is adequate for group comparison studies. The FS do not satisfy criteria as an eight-, seven- or six-item summed rating scale. Despite being based on sound clinical intuition, the lack of psychometric input into the development of the EDSS and FS has limited their usefulness as evaluative outcome measures in multiple sclerosis.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. E Munschauer III, R. H. Benedict, C. V Granger, and P. M Niewczyk Introduction to Best practice recommendations for the selection and management of patients with MS on natalizumab Multiple Sclerosis, November 1, 2009; 15(4_suppl): S1 - S6. [PDF]
|
|
|
|
 |
|
 J. F. Foley and D. W. Brandes Redefining functionality and treatment efficacy in multiple sclerosis Neurology, June 9, 2009; 72(23_Supplement_5): S1 - S11. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Minneboo, B. Uitdehaag, P Jongen, H Vrenken, D. Knol, M. van Walderveen, C. Polman, J. Castelijns, and F Barkhof Association between MRI parameters and the MS severity scale: a 12 year follow-up study Multiple Sclerosis, May 1, 2009; 15(5): 632 - 637. [Abstract] [PDF]
|
|
|
|
|
|
N. Koch-Henriksen No shortcuts to outcome in MS clinical trials? Neurology, February 24, 2009; 72(8): 686 - 687. [Full Text] [PDF]
|
|
|
|
|
|
O. Gray, G. McDonnell, and S. Hawkins Tried and tested: the psychometric properties of the multiple sclerosis impact scale (MSIS-29) in a population-based study Multiple Sclerosis, January 1, 2009; 15(1): 75 - 80. [Abstract] [PDF]
|
|
|
|
|
|
B Brochet, M. Deloire, M Bonnet, E Salort-Campana, J. Ouallet, K. Petry, and V Dousset Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study Multiple Sclerosis, November 1, 2008; 14(9): 1242 - 1249. [Abstract] [PDF]
|
|
|
|
|
|
J. J. Kragt, A. J. Thompson, X. Montalban, M. Tintore, J. Rio, C. H. Polman, and B.M.J. Uitdehaag Responsiveness and predictive value of EDSS and MSFC in primary progressive MS Neurology, March 25, 2008; 70(13_Part_2): 1084 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z Khaleeli, J Sastre-Garriga, O Ciccarelli, D H Miller, and A J Thompson Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis J. Neurol. Neurosurg. Psychiatry, October 1, 2007; 78(10): 1076 - 1082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rampello and A. Chetta Author Response Physical Therapy, May 1, 2007; 87(5): 558 - 559. [Full Text] [PDF]
|
|
|
|
|
|
M. Juha, S. Leszek, F. Sten, H. Jan, B. Jakob, F. Olof, and K. W. Maria Progression of non-age-related callosal brain atrophy in multiple sclerosis: a 9-year longitudinal MRI study representing four decades of disease development J. Neurol. Neurosurg. Psychiatry, April 1, 2007; 78(4): 375 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Hensiek, S. R. Seaman, L. F. Barcellos, A. Oturai, M. Eraksoi, E. Cocco, L. Vecsei, G. Stewart, B. Dubois, J. Bellman-Strobl, et al. Familial effects on the clinical course of multiple sclerosis Neurology, January 30, 2007; 68(5): 376 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. de Groot, H. Beckerman, B. M. J. Uitdehaag, H. C. W. de Vet, G. J. Lankhorst, C. H. Polman, and L. M. Bouter The usefulness of evaluative outcome measures in patients with multiple sclerosis Brain, October 1, 2006; 129(10): 2648 - 2659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M M Nieuwenhuis, H Van Tongeren, P S Sorensen, and M Ravnborg The Six Spot Step Test: a new measurement for walking ability in multiple sclerosis Multiple Sclerosis, August 1, 2006; 12(4): 495 - 500. [Abstract] [PDF]
|
|
|
|
|
|
V de Groot, H Beckerman, G J Lankhorst, C H Polman, and L M Bouter The initial course of daily functioning in multiple sclerosis: a three-year follow-up study Multiple Sclerosis, December 1, 2005; 11(6): 713 - 718. [Abstract] [PDF]
|
|
|
|
|
|
D A Gruenewald, I J Higginson, B Vivat, P Edmonds, and R E Burman Quality of life measures for the palliative care of people severely affected by multiple sclerosis: a systematic review Multiple Sclerosis, December 1, 2004; 10(6): 690 - 725. [Abstract] [PDF]
|
|
|
|
 |
|
 O.R. Pearson, M.E. Busse, R.W.M. van Deursen, and C.M. Wiles Quantification of walking mobility in neurological disorders QJM, August 1, 2004; 97(8): 463 - 475. [Full Text] [PDF]
|
|
|
|
|
|
C. McGuigan and M. Hutchinson Confirming the validity and responsiveness of the Multiple Sclerosis Walking Scale-12 (MSWS-12) Neurology, June 8, 2004; 62(11): 2103 - 2105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C McGuigan and M Hutchinson The multiple sclerosis impact scale (MSIS-29) is a reliable and sensitive measure J. Neurol. Neurosurg. Psychiatry, February 1, 2004; 75(2): 266 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Hobart, N Kalkers, F Barkhof, B Uitdehaag, C Polman, and A Thompson Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional C omposite Multiple Sclerosis, February 1, 2004; 10(1): 41 - 46. [Abstract] [PDF]
|
|
|
|
|
|
G. T. Ingle, V. L. Stevenson, D. H. Miller, and A. J. Thompson Primary progressive multiple sclerosis: a 5-year clinical and MR study Brain, November 1, 2003; 126(11): 2528 - 2536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M Gold, H. Schulz, A. Monch, K.-H. Schulz, and C. Heesen Cognitive impairment in multiple sclerosis does not affect reliability and validity of self-report health measures Multiple Sclerosis, August 1, 2003; 9(4): 404 - 410. [Abstract] [PDF]
|
|
|
|
|
|
A Riazi, J C Hobart, D L Lamping, R Fitzpatrick, and A J Thompson Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales Multiple Sclerosis, August 1, 2003; 9(4): 411 - 419. [Abstract] [PDF]
|
|
|
|
|
|
E L J Hoogervorst, M J Eikelenboom, B M J Uitdehaag, and C H Polman One year changes in disability in multiple sclerosis: neurological examination compared with patient self report J. Neurol. Neurosurg. Psychiatry, April 1, 2003; 74(4): 439 - 442. [Full Text] [PDF]
|
|
|
|
|
|
J Lechner-Scott, L Kappos, M Hofman, C H Polman, H Ronner, X Montalban, M Tintore, M Frontoni, C Buttinelli, M P Amato, et al. Can the Expanded Disability Status Scale be assessed by telephone? Multiple Sclerosis, April 1, 2003; 9(2): 154 - 159. [Abstract] [PDF]
|
|
|
|
|
|
M W Nortvedt and T Riise The use of quality of life measures in multiple sclerosis research Multiple Sclerosis, February 1, 2003; 9(1): 63 - 72. [Abstract] [PDF]
|
|
|
|
|
|
J. C. Hobart, A. Riazi, D. L. Lamping, R. Fitzpatrick, and A. J. Thompson Measuring the impact of MS on walking ability: The 12-Item MS Walking Scale (MSWS-12) Neurology, January 14, 2003; 60(1): 31 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Riazi, J C Hobart, D L Lamping, R Fitzpatrick, and A J Thompson Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples J. Neurol. Neurosurg. Psychiatry, December 1, 2002; 73(6): 701 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J Thompson Developing clinical outcome measures in multiple sclerosis: an evolving process Multiple Sclerosis, October 1, 2002; 8(5): 357 - 358. [PDF]
|
|
|
|
|
|
R A Rudick, G Cutter, and S Reingold The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials Multiple Sclerosis, October 1, 2002; 8(5): 359 - 365. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Bonneville, D. M. Moriarty, B. S.Y. Li, J. S. Babb, R. I. Grossman, and O. Gonen Whole-Brain N-Acetylaspartate Concentration: Correlation with T2-Weighted Lesion Volume and Expanded Disability Status Scale Score in Cases of Relapsing-Remitting Multiple Sclerosis AJNR Am. J. Neuroradiol., March 1, 2002; 23(3): 371 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E M Cheng, R D Hays, L W Myers, G W Ellison, M Beckstrand, and B G Vickrey Factors related to agreement between self-reported and conventional Expanded Disability Status Scale (EDSS) scores Multiple Sclerosis, December 1, 2001; 7(6): 405 - 410. [Abstract] [PDF]
|
|
|
|
|
|
E L. Hoogervorst, N F Kalkers, L M. van Winsen, B M. Uitdehaag, and C H Polman Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis Multiple Sclerosis, October 1, 2001; 7(5): 335 - 339. [Abstract] [PDF]
|
|
|
|
|
|
J Hobart, J Freeman, D Lamping, R Fitzpatrick, and A Thompson The SF-36 in multiple sclerosis: why basic assumptions must be tested J. Neurol. Neurosurg. Psychiatry, September 1, 2001; 71(3): 363 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Freeman, J. C. Hobart, and A. J. Thompson Does adding MS-specific items to a generic measure (the SF-36) improve measurement? Neurology, July 10, 2001; 57(1): 68 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bowen, L. Gibbons, A. Gianas, and G. H Kraft Self-administered Expanded Disability Status Scale with functional system scores correlates well with a physician-administered test Multiple Sclerosis, June 1, 2001; 7(3): 201 - 206. [Abstract] [PDF]
|
|
|
|
 |
|
 J. A. Cohen, G. R. Cutter, J. S. Fischer, A. D. Goodman, F. R. Heidenreich, A. J. Jak, J. E. Kniker, M. F. Kooijmans, J. M. Lull, A. W. Sandrock, et al. Use of the Multiple Sclerosis Functional Composite as an Outcome Measure in a Phase 3 Clinical Trial Arch Neurol, June 1, 2001; 58(6): 961 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hobart, D. Lamping, R. Fitzpatrick, A. Riazi, and A. Thompson The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure Brain, May 1, 2001; 124(5): 962 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.L.J. Hoogervorst, L.M.L. van Winsen, M.J. Eikelenboom, N.F. Kalkers, B.M.J. Uitdehaag, and C.H. Polman Comparisons of patient self-report, neurologic examination, and functional impairment in MS Neurology, April 10, 2001; 56(7): 934 - 937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S M Gold, C Heesen, H Schulz, U Guder, A Monch, J Gbadamosi, C Buhmann, and K H Schulz Disease specific quality of life instruments in multiple sclerosis: Validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS) Multiple Sclerosis, April 1, 2001; 7(2): 119 - 130. [Abstract] [PDF]
|
|
|
|
|
|
A. J. Manson, H. Hanagasi, K. Turner, P. N. Patsalos, P. Carey, N. Ratnaraj, and A. J. Lees Intravenous apomorphine therapy in Parkinson's disease: Clinical and pharmacokinetic observations Brain, February 1, 2001; 124(2): 331 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J Thompson Neurological rehabilitation: from mechanisms to management J. Neurol. Neurosurg. Psychiatry, December 1, 2000; 69(6): 718 - 722. [Full Text] [PDF]
|
|